Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. We at Vidac are passionate about translating breakthrough science into innovative therapies that address major unmet medical needs.
Our breakthrough platform technology uniquely targets hexokinase 2 (HK2), a master regulator of metabolism in proliferating cells (e.g., cancer cells) that is absent from most normal cells. Modulating the binding of HK2 to the mitochondria, the 'power house' of the cell, triggers tumor apoptosis and reduces metabolite immunosuppression in the tumor microenvironment, without affecting the surrounding healthy tissue. This technology holds a promise of delivering first-in-class drugs that are both efficacious and well tolerated.
Vidac was founded by Prof. Max Herzberg, one of the founding fathers of the Israel life sciences industry, and licensed components of its technology from two top Israeli universities, Tel Aviv University and Ben Gurion University.
Vidac's lead drug, VDA-1102 ointment, is undergoing clinical trials in subjects with actinic keratosis (AK), an early form of skin cancer. Following a successful proof-of-concept Phase 2a study, a confirmatory Phase 2b trials is being conducted in 2018.
Phase 2B trial on AK was successfully conducted in 2019. A Phase 2c with a slight different formulation to enhance skin permeability is planned for 2021 when Corona Pandemics will permit.
A Phase 2 on CTCL was initiated in Dec 2020 for treatment of the early stage of CTCL.
The drug is being developed under an IND from the FDA.Factsheet